CAR T-cell Therapy

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

The purchase secures full control of anito-cel, a BCMA-directed cell therapy under FDA review with a December 23 action date.